# Tune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tune-therapeutics

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.tunetx.com
- Total disclosed funding: $160M
- Latest round: Series B (Jan 13, 2025)
- Investors on record: 7

## About

Based in North Carolina, US, and founded in 2020 by Akira Matsuno, Charles Gersbach, and Fyodor Urnov, Tune Therapeutics Inc. develops gene and cell therapies that leverage epigenetic programming for the treatment of genetic diseases and cancers. In January 2025, Tune Therapeutics, Inc. raised USD 175 million in series B funding led by returning investor New Enterprise Associates, with participation from other new investors Yosemite Management, Regeneron Ventures, and Hevolution Foundation. As of December 2021, Tune Therapeutics has 35 employees, and it is led by its CEO, Matt Kane.

Tune Therapeutics offers a proprietary platform, TEMPO, that operates as an epigenomic therapy to fine-tune gene expression in the emerging class of epitherapeutics.

The company will use the funding to support its medical pipeline's development.

## Funding rounds

- Series B, Jan 13, 2025, $120M — New Enterprise Associates, Yosemite Management, Hevolution Foundation, Regeneron Ventures
- Series A, Dec 2, 2021, $40M — New Enterprise Associates, Hatteras Venture Partners, Mission Biocapital, Emerson Collective

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A
- Emerson Collective — Series A
- Yosemite Management (https://capitalatlas.ai/funds/yosemite-management) — Series B
- Hevolution Foundation — Series B
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series B